A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or General Tonic-clonic Seizures

Trial Profile

A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or General Tonic-clonic Seizures

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Lacosamide (Primary) ; Carbamazepine
  • Indications Partial epilepsies; Tonic-clonic epilepsy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 05 Dec 2017 Results of post- hoc analysis evaluating the serum lipid profile after 12 months of LCM or controlled-released CBZ (CBZ-CR) monotherapy in adults with newly diagnosed epilepsy presented at the 71st Annual Meeting of the American Epilepsy Society
    • 05 Dec 2017 Results of post- hoc analysis assessing the tolerability of lacosamide (LCM) and controlled-released carbamazepine (CBZ-CR) monotherapy by number of additional medical conditions in adults with newly diagnosed epilepsy presented at the 71st Annual Meeting of the American Epilepsy Society
    • 28 Apr 2017 Results of sub analysis (n=886) stratified by baseline disease severity presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top